Archives
RCT | Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction.
3 Aug, 2022 | 14:06h | UTC
Commentary on Twitter
No one wants to add meds just so you can add more meds. BUT, adding patiromer in select patients with HFrEF so you can optimize GDMT sure is compelling… 🤔 https://t.co/79gSEwon4y
— ATRIUM Cardiology (@ATRIUMRx) July 29, 2022
M-A | Global prevalence of non-tuberculous mycobacteria in adults with non-cystic fibrosis bronchiectasis 2006–2021.
3 Aug, 2022 | 14:04h | UTC
Study shows the incidence of obesity among US children is increasing.
3 Aug, 2022 | 14:00h | UTCChanges in the Incidence of Childhood Obesity – Pediatrics
Original Study: Childhood Obesity Rate in the U.S. Higher Now Than 12 Years Prior – HealthDay
RCT | Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy.
3 Aug, 2022 | 14:02h | UTCSintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Online first: #Sintilimab plus #bevacizumab #biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell #lungcancer #NSCLC who progressed on EGFR TKI therapy: first interim results from ORIENT-31 https://t.co/5VwmLCcGW5 pic.twitter.com/RWeeyfuC6i
— The Lancet Oncology (@TheLancetOncol) August 2, 2022
Review | Management of alcohol-related liver disease and its complications.
3 Aug, 2022 | 13:56h | UTCManagement of Alcohol-Related Liver Disease and Its Complications – Clinical Drug Investigation
Related Guideline: Management of alcohol-related liver disease: the French Association for the Study of the Liver and the French Alcohol Society clinical guidelines – Liver International
Commentary on Twitter (thread – click for more)
Excellent review about the Management of Alcohol-Related Liver Disease and Its Complications carried out by Dr. Cabezas.https://t.co/VICukJ3jEt
Key points:
1. It is still a stigmatized condition with underlying pathology.@AEEHLiver @sepdigestiva #LiverTwitter …— Javier Crespo (@DrJavierCrespo) July 29, 2022
Cohort Study | Association between early left ventricular ejection fraction improvement after transcatheter aortic valve replacement and 5-year clinical outcomes.
3 Aug, 2022 | 13:58h | UTCAssociation Between Early Left Ventricular Ejection Fraction Improvement After Transcatheter Aortic Valve Replacement and 5-Year Clinical Outcomes – JAMA Cardiology (link to abstract – $ for full-text)
Commentary: Early LV Recovery After TAVI Points to Better 5-Year Survival – TCTMD
Commentary on Twitter
In patients with severe #aorticstenosis and left ventricular ejection fraction (LVEF) less than 50%, 1 in 3 experience LVEF improvement within 1 month after TAVR. Early LVEF improvement is associated with lower 5-year all-cause and cardiac death. https://t.co/81H6roA8nV
— JAMA Cardiology (@JAMACardio) July 27, 2022
Trends in thoracic aortic aneurysm hospital admissions, interventions and mortality in England between 1998 to 2020: An observational study.
3 Aug, 2022 | 13:55h | UTC
Cohort Study | Incidence of acute chest syndrome in children with sickle cell disease following implementation of the 13-valent pneumococcal conjugate vaccine.
3 Aug, 2022 | 13:53h | UTC
Commentary on Twitter
#OrigInvestigation: Reduction of acute chest syndrome incidence in children with sickle-cell disease following 13-valent pneumococcal conjugate vaccine (PCV13) implementation in France. https://t.co/MuG6T0g5FU
— JAMA Network Open (@JAMANetworkOpen) August 2, 2022
WHO Guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations.
2 Aug, 2022 | 12:41h | UTCNews Release: WHO publishes new guidelines on HIV, hepatitis and STIs for key populations – World Health Organization
Severe acute hepatitis of unknown etiology in children—what is known?
2 Aug, 2022 | 12:39h | UTCSevere acute hepatitis of unknown aetiology in children—what is known? – BMC Medicine
Related:
A Case Series of Children with Acute Hepatitis and Human Adenovirus Infection – New England Journal of Medicine (link to abstract – $ for full-text)
Clinical Spectrum of Children with Acute Hepatitis of Unknown Cause – New England Journal of Medicine (link to abstract – $ for full-text)
Severe acute hepatitis of unknown aetiology in children – Multi-country – World Health Organization
Sudden onset hepatitis in children – Nature Reviews Gastroenterology & Hepatology (if the link is paywalled, try this one)
Outbreak of hepatitis in children: clinical course of children with acute liver failure admitted to the intensive care unit – Intensive Care Medicine (if the link is paywalled, try this one)
Investigating Acute Hepatitis of Unknown Origin in Children – American Society for Microbiology
What’s sending kids to hospitals with hepatitis—coronavirus, adenovirus, or both? – Science
Puzzling pediatric hepatitis cases echo an earlier mysterious illness – STAT
Why COVID is a key suspect in severe hepatitis cases in kids worldwide – CBC
Hepatitis outbreak in children: What do we know so far? – Imperial College London
Explaining the unexplained hepatitis in children – The Lancet Infectious Diseases
Unexplained hepatitis cases in kids rise to 348 in 20 nations – CIDRAP
Multi-Country – Acute, severe hepatitis of unknown origin in children – World Health Organization
WHO says 12 countries have reported unusual cases of hepatitis in kids – STAT
Could Mysterious Hepatitis Cases be Triggered by COVID-19? – Health Policy Watch
U.S., U.K. investigating unusual cases of hepatitis in young children – STAT
Mysterious liver illness seen in kids in US, Europe – Associated Press
Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019.
2 Aug, 2022 | 12:37h | UTCNews Release: Chronic lung disease remains major public health problem – BMJ Newsroom
Commentary on Twitter
New research finds that despite the decreasing burden of COPD, this disease remains a major public health problem, especially in countries with a low sociodemographic index https://t.co/uUkQYCSmBY
— The BMJ (@bmj_latest) July 30, 2022
M-A | GLP1 receptor agonists are associated with increased risk of progression of retinopathy in patients with type 2 diabetes.
2 Aug, 2022 | 12:32h | UTCProgression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes – A systematic review and meta-analysis – Journal of Diabetes and its Complications (link to abstract – $ for full-text)
Commentary: GLP1 RA use tied to increased risk of rapidly worsening retinopathy in type 2 diabetes – Medical Dialogues
Retrospective Cohort Study | Syncope and the risk of subsequent motor vehicle crash.
2 Aug, 2022 | 12:33h | UTCSyncope and the Risk of Subsequent Motor Vehicle Crash: A Population-Based Retrospective Cohort Study – JAMA Internal Medicine (free for a limited period)
Editorial: Driving Safety After an Acute Illness—This Is Our Lane – JAMA Internal Medicine (free for a limited period)
Commentary on Twitter
"I fainted…am I safe to drive?" Study found that 9,223 drivers with an ED visit for syncope had subsequent crash risks no different than controls, suggesting more stringent driving restrictions might not be justified. https://t.co/T0GUJ63Nci
— JAMA Internal Medicine (@JAMAInternalMed) August 1, 2022
Digital teaching in medical education: scientific literature landscape review.
2 Aug, 2022 | 12:23h | UTCNews Release: Digital teaching in medical education: A literature review – JMIR Publications
M-A | Planned delivery or expectant management in preeclampsia.
2 Aug, 2022 | 12:28h | UTC
Commentary on Twitter
Planned delivery or expectant management in preeclampsia: an individual participant data meta-analysis https://t.co/djWXjReZAM pic.twitter.com/UdjsqcXDnH
— AJOG (@AJOG_thegray) July 26, 2022
Cohort Study | Association of elevated amyloid and tau positron emission tomography signal with near-term development of Alzheimer disease symptoms in older adults without cognitive impairment.
2 Aug, 2022 | 12:26h | UTCAssociation of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment – JAMA Neurology (link to abstract – $ for full-text)
Commentary on Twitter
Study found that Aβ and tau PET positivity in cognitively unimpaired individuals was associated with near-term progression to mild cognitive impairment and, among those who do not show such categorical change, longitudinal cognitive decline. https://t.co/sKpST7e4Nh
— JAMA Neurology (@JAMANeuro) July 30, 2022
M-A | Perioperative care bundles for the prevention of surgical-site infections.
2 Aug, 2022 | 12:30h | UTC
Guideline | Role of IVIG in the management of Rh- and ABO-mediated hemolytic disease of the newborn.
2 Aug, 2022 | 12:18h | UTC
Review | Massive Open Online Courses (MOCCs) for health worker education in low- and middle-income countries.
2 Aug, 2022 | 12:21h | UTC
An updated review of subglottic stenosis: etiology, evaluation, and management.
2 Aug, 2022 | 12:08h | UTCAn Updated Review of Subglottic Stenosis: Etiology, Evaluation, and Management – Current Pulmonology Reports (if the link is paywalled, try this one)
Position Paper | Practical considerations, indications, and future perspectives for leadless and extravascular cardiac implantable electronic devices.
2 Aug, 2022 | 12:15h | UTC
Saudi consensus recommendations on the management of multiple sclerosis in children and adolescents.
2 Aug, 2022 | 12:13h | UTC
Brief Review | Evolution of sedation management in the intensive care unit.
2 Aug, 2022 | 12:07h | UTCEvolution of sedation management in the intensive care unit (ICU) – Intensive Care Medicine (if the link is paywalled, try this one)
Commentary on Twitter
Evolution of sedation practices in #ICU, from keeping critical patients deeply sedated to let them rest to wake them up on minimal sedation, assuring comfort but promoting liberation from MV & recovery/survivorship
📎 https://t.co/IlpSkJEfnCPS free to read link tomorrow #FOAMcc pic.twitter.com/GFVxsEibdH
— Intensive Care Medicine (@yourICM) July 29, 2022
Systematic Review | Physical activity for treatment of irritable bowel syndrome.
2 Aug, 2022 | 12:12h | UTCPhysical activity for treatment of irritable bowel syndrome – Cochrane Library
RCT | Safety and efficacy of Tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan.
2 Aug, 2022 | 12:05h | UTCSafety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)
See also (note: the dulaglutide dosage used in this trial was probably suboptimal): Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)
Related:
Tirzepatide Once Weekly for the Treatment of Obesity – New England Journal of Medicine
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Online—Safety and efficacy of #tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 #diabetes in #Japan (#SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial https://t.co/r4v4QUsl5q #T2D pic.twitter.com/k6ihWy2vem
— The Lancet Diabetes & Endocrinology (@TheLancetEndo) July 31, 2022